{
    "nct_id": "NCT02977468",
    "official_title": "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study",
    "brief_title": "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer",
    "cancer_type_display": "A study for patients with newly diagnosed, early-stage, treatment-naive Triple Negative Breast Cancer (TNBC).",
    "cancer_tags": [
      "Triple Negative Breast Cancer"
    ],
    "link_to_trial": "https://clinicaltrials.gov/study/NCT02977468",
    "phase": "Phase 1",
    "recruitment_status": "RECRUITING",
    "last_update_date": "2024-06-20",
    "enrollment": 15,
    "min_age": 21,
    "max_age": 80,
    "sex": "FEMALE",
    "is_metastatic_allowed": false,
    "performance_status_scale": "ECOG",
    "performance_status_values": [
      0,
      1
    ],
    "min_prior_lines": 0,
    "max_prior_lines": 0,
    "prior_treatments_required": null,
    "prior_treatments_excluded": [
      "prior anti-cancer therapy",
      "investigational agents",
      "radiation therapy",
      "breast resection",
      "prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent"
    ],
    "principal_investigator": "Eileen Connolly, MD",
    "site_name": "Emory University",
    "contact_email": "epc2116@cumc.columbia.edu",
    "contact_phone": "212-305-5050",
    "locations": [
      {
        "facility": "Emory University",
        "status": "RECRUITING",
        "city": "Atlanta",
        "state": "Georgia",
        "zip": "30322",
        "country": "United States",
        "contacts": [
          {
            "name": "Jane Meisel, MD",
            "role": "CONTACT"
          }
        ],
        "geoPoint": {
          "lat": 33.749,
          "lon": -84.38798
        }
      },
      {
        "facility": "Loyola University Chicago",
        "status": "RECRUITING",
        "city": "Maywood",
        "state": "Illinois",
        "zip": "60153",
        "country": "United States",
        "contacts": [
          {
            "name": "William Small, MD",
            "role": "CONTACT"
          }
        ],
        "geoPoint": {
          "lat": 41.8792,
          "lon": -87.84312
        }
      },
      {
        "facility": "Columbia University Irving Medical Center",
        "status": "RECRUITING",
        "city": "New York",
        "state": "New York",
        "zip": "10032",
        "country": "United States",
        "contacts": [
          {
            "name": "Eileen Connolly, MD",
            "role": "CONTACT",
            "phone": "212-305-5050",
            "email": "epc2116@cumc.columbia.edu"
          },
          {
            "name": "Mariamne Reyna",
            "role": "CONTACT",
            "phone": "646-317-4244",
            "email": "mo2213@cumc.columbia.edu"
          },
          {
            "name": "Eileen Connolly, MD, PhD",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "geoPoint": {
          "lat": 40.71427,
          "lon": -74.00597
        }
      }
    ],
    "key_inclusion_summary": [
      "Histologically proven invasive breast carcinoma with triple negative receptor status.",
      "Clinically â‰¤ 3 cm unifocal lesion.",
      "Clinically node negative, no evidence of metastatic disease.",
      "ECOG performance status of 0 or 1.",
      "No prior anti-cancer therapy."
    ],
    "key_exclusion_summary": [
      "Multifocal disease or primary lesion > 3 cm.",
      "Pathologically proven nodal disease or metastatic disease.",
      "Has a known additional malignancy that is progressing or requires active treatment in the last 5 years.",
      "Has active autoimmune disease that has required systemic treatment in the past 2 years.",
      "Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent."
    ]
  }